Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
USTAP CD
2023-503380-42-00Phase 4Authorised
- Sponsor
- GETAID
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of ustekinumab in Crohn's disease and anal fistula, sponsored by GETAID. Planned start Aug 2024; status: authorised.
02
Drugs
ustekinumab
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on 2023-503380-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503380-42-00.